Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1979 Apr;15(4):597–602. doi: 10.1128/aac.15.4.597

Antifungal Activity of Tioconazole (UK-20,349), a New Imidazole Derivative

S Jevons 1, G E Gymer 1, K W Brammer 1, D A Cox 1, M R G Leeming 1
PMCID: PMC352717  PMID: 464592

Abstract

Tioconazole (UK-20,349), a new antifungal imidazole derivative, was compared with miconazole for activity in vitro against Candida spp., Torulopsis glabrata, Cryptococcus neoformans, Aspergillus spp., and dermatophyte fungi (Trichophyton spp. and Microsporum spp.). Tioconazole was more active than miconazole against all the fungal species examined except Aspergillus, against which both agents showed similar activity. Both tioconazole and miconazole inhibited the growth of all fungi examined at concentrations well below their quoted minimum inhibitory concentrations. Their activity against fungi in vivo was investigated in mice infected systemically with Candida albicans. Both agents significantly reduced the numbers of viable Candida cells recoverable from the kidneys of infected animals, with tioconazole producing a generally more marked reduction. After administration of a single oral dose (25 mg/kg) to beagle dogs or white mice, higher and more sustained circulating levels of bioactive drug were detectable of tioconazole than of miconazole. These observations suggest that tioconazole may have potential in the treatment of both superficial and systemic mycoses in humans.

Full text

PDF
601

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDRIOLE V. T., KRAVETZ H. M. The use of amphotericin B in man. JAMA. 1962 Apr 28;180:269–272. doi: 10.1001/jama.1962.03050170001001. [DOI] [PubMed] [Google Scholar]
  2. BLANK H., SMITH J. G., Jr, ROTH F. J., Jr, ZAIAS N. Griseofulvin for the systemic treatment of dermatomycoses. J Am Med Assoc. 1959 Dec 19;171:2168–2173. doi: 10.1001/jama.1959.03010340012003. [DOI] [PubMed] [Google Scholar]
  3. Burgess J. L., Birchall R. Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function. Am J Med. 1972 Jul;53(1):77–84. [PubMed] [Google Scholar]
  4. David L. M., Veien N. K., Schmidt J. D., Murtishaw W., Smith E. B. Topical clotrimazole in dermatophytosis. Curr Ther Res Clin Exp. 1973 Mar;15(3):133–137. [PubMed] [Google Scholar]
  5. Deresinski S. C., Lilly R. B., Levine H. B., Galgiani J. N., Stevens D. A. Treatment of fungal meningitis with miconazole. Arch Intern Med. 1977 Sep;137(9):1180–1185. [PubMed] [Google Scholar]
  6. Evans E. G., Watson D. A., Matthews N. R. Pulmonary aspergillomata in a child treated with clotrimazole. Br Med J. 1971 Dec 4;4(5787):599–600. doi: 10.1136/bmj.4.5787.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fredriksson T. Topical treatment with BAY b 5097, a new broad spectrum antimycotic agent. Br J Dermatol. 1972 Jun;86(6):628–630. doi: 10.1111/j.1365-2133.1972.tb05079.x. [DOI] [PubMed] [Google Scholar]
  8. Fulton J. E., Jr Miconazole therapy for endemic fungal disease. Arch Dermatol. 1975 May;111(5):596–598. [PubMed] [Google Scholar]
  9. Hoeprich P. D., Goldstein E. Miconazole therapy for coccidioidomycosis. JAMA. 1974 Nov 25;230(8):1153–1157. [PubMed] [Google Scholar]
  10. Hoeprich P. D., Huston A. C. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. J Infect Dis. 1976 Oct;134(4):336–341. doi: 10.1093/infdis/134.4.336. [DOI] [PubMed] [Google Scholar]
  11. Holt R. J. Recent developments in antimycotic chemotherapy. Infection. 1974;2(2):95–107. doi: 10.1007/BF01642028. [DOI] [PubMed] [Google Scholar]
  12. Marget W., Adam D. Bay B 5097, a new orally applicable antifungal substance with broadspectrum activity. Preliminary clinical and laboratory experiences in children. Acta Paediatr Scand. 1971 May;60(3):341–345. doi: 10.1111/j.1651-2227.1971.tb06668.x. [DOI] [PubMed] [Google Scholar]
  13. Schär G., Kayser F. H., Dupont M. C. Antimicrobial activity of econazole and miconazole in vitro and in experimental candidiasis and aspergillosis. Chemotherapy. 1976;22(3-4):211–220. doi: 10.1159/000221928. [DOI] [PubMed] [Google Scholar]
  14. Shadomy S. In vitro studies with 5-fluorocytosine. Appl Microbiol. 1969 Jun;17(6):871–877. doi: 10.1128/am.17.6.871-877.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Shadomy S., Paxton L., Espinel-Ingroff A., Shadomy H. J. In vitro studies with miconazole and miconazole nitrate. J Antimicrob Chemother. 1977 Mar;3(2):147–152. doi: 10.1093/jac/3.2.147. [DOI] [PubMed] [Google Scholar]
  16. Symoens J. Clinical and experimental evidence on miconazole for the treatment of systemic mycoses: a review. Proc R Soc Med. 1977;70 (Suppl 1):4–8. [PMC free article] [PubMed] [Google Scholar]
  17. Van Cutsem J. M., Thienpont D. Miconazole, a broad-spectrum antimycotic agent with antibacterial activity. Chemotherapy. 1972;17(6):392–404. doi: 10.1159/000220875. [DOI] [PubMed] [Google Scholar]
  18. Wallenburg H. C., Wladimiroff J. W. Recurrence of vulvovaginal candidosis during pregnancy. Comparison of miconazole vs nystatin treatment. Obstet Gynecol. 1976 Oct;48(4):491–494. [PubMed] [Google Scholar]
  19. Weuta H. Klinische Erfahrungen mit der systemischen Verabreichung von Clotrimazol. Pharmakokinetik, Wirkung, Verträglichkeit. Arzneimittelforschung. 1974 Apr;24(4):540–545. [PubMed] [Google Scholar]
  20. el-Mahgoub S. Laboratory and clinical experience with clotrimazole (Bay b 5097). Sabouraudia. 1972 Nov;10(3):212–217. doi: 10.1080/00362177285190431. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES